Breast Implants Trials
CytRx’s INNO-206 Rapidly Shrinks Human Tumors In An Animal Model Of Multiple Myeloma
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 …
Marc Bern is on Court TV-Breast Implant